• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Scott Cormack, Oncogenex Pharmaceuticals


Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-06-01-2009
Volume 0
Issue 0

I began my career with an interest in medicine and pharmaceutical sciences.

Scott Cormack

President and CEO, OncoGenex Pharmaceuticals

I began my career with an interest in medicine and pharmaceutical sciences. In considering going into post-secondary education, I was introduced to a small biotech company pursuing immune modulation. I spoke with the company and was offered a position. The rest, as they say, is history.

Later, I cofounded OncoGenex with Martin Gleave. Since then, I've led OncoGenex through significant corporate milestones, including serial rounds of private financing, and taken the corporation from preclinical through completion of multiple Phase II clinical trials.

I believe in pursuing novel therapeutics to materially change disease management. OncoGenex's product pipeline is comprised of a majority of product candidates designed to inhibit novel targets. The company's randomized Phase II data in prostate cancer, which showed a 40 percent reduction in the rate of death compared to the gold standard therapy, demonstrates the success of this approach.

Related Videos
Related Content